Abstract: The present invention relates to one or more combination treatments of cancer patients with a compound of formula (I), and an allosteric inhibitor or an immune checkpoint molecule, wherein R1 and R2 are as described herein.

Abstract: A combination comprising a FAK inhibitor and a BTK inhibitor, a pharmaceutical composition and a kit, and a method for treating a disease such as esophageal cancer using the combination.

Abstract: The present disclosure provides a pharmaceutical composition comprising a Bcl-2/Bcl-xL inhibitor, a chemotherapeutic agent, and a pharmaceutically acceptable carrier. The present disclosure also provides a method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a Bcl-2/Bcl-xL inhibitor and a therapeutically effective amount of a chemotherapeutic agent. The present disclosure also provides use of a combination of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent in the manufacture of an anti-tumor medicament. In the present disclosure, a significantly enhanced anti-tumor effect can be achieved by administration of a Bcl-2/Bcl-xL inhibitor in combination with a chemotherapeutic agent.